Hyperestrogenism is associated with sexual function impairment in men-findings from a cross-sectional, real-life study.
erectile dysfunction
estradiol
estrogens
sex hormones
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
01 Jun 2023
01 Jun 2023
Historique:
revised:
08
05
2023
received:
11
01
2023
accepted:
26
05
2023
pubmed:
1
6
2023
medline:
1
6
2023
entrez:
1
6
2023
Statut:
aheadofprint
Résumé
Hyperestrogenism is believed to be harmful to male sexuality. We aimed to investigate the prevalence of and the impact of hyperestrogenism on sexual functioning in a cohort of men seeking medical attention for new-onset erectile dysfunction. Data from 547 men seeking first medical help for new-onset erectile dysfunction at a single andrology center were analyzed. Patients were assessed with a thorough medical and sexual history. Comorbidities were scored with the Charlson comorbidity index. All patients completed the International index of erectile function; the International index of erectile function-erectile function domain was categorized according to Cappelleri's criteria. Circulating hormones were measured in every patient. Hyperestrogenism was defined as estradiol levels >42.6 pg/mL (Tan et al., 2015). Descriptive statistics and logistic/linear regression models tested the association between hyperestrogenism and International index of erectile function domains score. Overall, 96 (17.6%) participants had serum estrogen levels suggestive of hyperestrogenism. Men with hyperestrogenism were older (median [interquartile range]: 46 [35-59] vs. 44 [31-56] years; p < 0.001), had a higher rate of comorbidities (Charlson comorbidity index ≥1: 26.0% vs. 7.4%; p < 0.001), and higher serum total testosterone values (5.4 [5.2-8.0] vs. 4.3 [4.1-5.7] ng/mL; p = 0.01) than those with normal estradiol values. A higher prevalence of severe erectile dysfunction (135 [29.9%] vs. 47 [48.9%] men; p = 0.01) and of hypogonadism (22 [4.8%] vs. 6 [6.3%] men; p = 0.004) were found in men with hyperestrogenism. Serum estradiol levels were positively correlated with total testosterone levels (β = 0.26, p < 0.001) but negatively correlated with International index of erectile function-orgasmic function (β = -0.24, p = 0.002) and International index of erectile function-erectile function scores (β = -0.03, p < 0.001). When International index of erectile function scores was used to stratify erectile dysfunction patients, hyperestrogenism (odds ratio 2.44, p = 0.02) was associated with severe erectile dysfunction. One out of five men seeking first medical help for erectile dysfunction showed elevated serum estradiol values suggestive of hyperestrogenism. Hyperestrogenism was associated with health-significant comorbidities, orgasmic function impairment, and erectile dysfunction severity.
Sections du résumé
BACKGROUND
BACKGROUND
Hyperestrogenism is believed to be harmful to male sexuality. We aimed to investigate the prevalence of and the impact of hyperestrogenism on sexual functioning in a cohort of men seeking medical attention for new-onset erectile dysfunction.
MATERIALS AND METHODS
METHODS
Data from 547 men seeking first medical help for new-onset erectile dysfunction at a single andrology center were analyzed. Patients were assessed with a thorough medical and sexual history. Comorbidities were scored with the Charlson comorbidity index. All patients completed the International index of erectile function; the International index of erectile function-erectile function domain was categorized according to Cappelleri's criteria. Circulating hormones were measured in every patient. Hyperestrogenism was defined as estradiol levels >42.6 pg/mL (Tan et al., 2015). Descriptive statistics and logistic/linear regression models tested the association between hyperestrogenism and International index of erectile function domains score.
RESULTS
RESULTS
Overall, 96 (17.6%) participants had serum estrogen levels suggestive of hyperestrogenism. Men with hyperestrogenism were older (median [interquartile range]: 46 [35-59] vs. 44 [31-56] years; p < 0.001), had a higher rate of comorbidities (Charlson comorbidity index ≥1: 26.0% vs. 7.4%; p < 0.001), and higher serum total testosterone values (5.4 [5.2-8.0] vs. 4.3 [4.1-5.7] ng/mL; p = 0.01) than those with normal estradiol values. A higher prevalence of severe erectile dysfunction (135 [29.9%] vs. 47 [48.9%] men; p = 0.01) and of hypogonadism (22 [4.8%] vs. 6 [6.3%] men; p = 0.004) were found in men with hyperestrogenism. Serum estradiol levels were positively correlated with total testosterone levels (β = 0.26, p < 0.001) but negatively correlated with International index of erectile function-orgasmic function (β = -0.24, p = 0.002) and International index of erectile function-erectile function scores (β = -0.03, p < 0.001). When International index of erectile function scores was used to stratify erectile dysfunction patients, hyperestrogenism (odds ratio 2.44, p = 0.02) was associated with severe erectile dysfunction.
CONCLUSIONS
CONCLUSIONS
One out of five men seeking first medical help for erectile dysfunction showed elevated serum estradiol values suggestive of hyperestrogenism. Hyperestrogenism was associated with health-significant comorbidities, orgasmic function impairment, and erectile dysfunction severity.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Andrology published by Wiley Periodicals LLC on behalf of American Society of Andrology and European Academy of Andrology.
Références
Morgentaler A, Traish A, Hackett G, Jones TH, Ramasamy R. Diagnosis and treatment of testosterone deficiency: updated recommendations from the Lisbon 2018 International Consultation for Sexual Medicine. Sex Med Rev. 2019;7(4):636-649. doi:10.1016/j.sxmr.2019.06.003
Traish AM. Benefits and health implications of testosterone therapy in men with testosterone deficiency. Sex Med Rev. 2018;6(1):86-105. doi:10.1016/j.sxmr.2017.10.001
Russell N, Grossmann M. Mechanisms in endocrinology: estradiol as a male hormone. Eur J Endocrinol. 2019;181(1):R23-R43. doi:10.1530/EJE-18-1000
Tang X, Fang M, Cheng R, et al. Iron-deficiency and estrogen are associated with ischemic stroke by up-regulating transferrin to induce hypercoagulability. Circ Res. 2020;127(5):651-663. doi:10.1161/CIRCRESAHA.119.316453
Laouali N, Brailly-Tabard S, Helmer C, et al. Oestradiol level, oestrogen receptors, and mortality in elderly men: the three-city cohort study. Clin Endocrinol (Oxf). 2018;89(4):514-525. doi:10.1111/cen.13797
Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem. 2007;102(4):899-911. 10.1002/jcb.21529
Salonia A, Gallina A, Briganti A, et al. Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy. Cancer. 2011;117(22):5029-5038. 10.1002/cncr.26136
Belladelli F, Del Giudice F, Kasman A, Salonia A, Eisenberg ML. The association between testosterone, estradiol and their ratio and mortality among US men. Andrologia. 2021;53(4):e13993. 10.1111/and.13993
Foresta C, Caretta N, Rossato M, Garolla A, Ferlin A. Role of androgens in erectile function. J Urol. 2004;171(6 pt 1):2358-2362. quiz 2435. 10.1097/01.ju.0000124323.02868.68
Salonia A, Rastrelli G, Hackett G, et al. Paediatric and adult-onset male hypogonadism. Nat Rev Dis Primer. 2019;5(1):38. 10.1038/s41572-019-0087-y
Govers LC, Phillips TR, Mattiske DM, et al. A critical role for estrogen signaling in penis development. FASEB J. 2019;33(9):10383-10392. 10.1096/fj.201802586RR
Chen T, Wu F, Wang X, et al. Different levels of estradiol are correlated with sexual dysfunction in adult men. Sci Rep. 2020;10(1):12660. 10.1038/s41598-020-69712-6
Salonia A, Bettocchi C, Boeri L, et al. European Association of Urology guidelines on sexual and reproductive health-2021 update: male sexual dysfunction. Eur Urol. 2021;80(3):333-357. 10.1016/j.eururo.2021.06.007
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. 10.1016/0021-9681(87)90171-8
Salonia A, Castagna G, Saccà A, et al. Is erectile dysfunction a reliable proxy of general male health status? The case for the International index of erectile function-erectile function domain. J Sex Med. 2012;9(10):2708-2715. 10.1111/j.1743-6109.2012.02869.x
Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666-3672. 10.1210/jcem.84.10.6079
Tan RS, Cook KR, Reilly WG. High estrogen in men after injectable testosterone therapy: the low T experience. Am J Mens Health. 2015;9(3):229-234. 10.1177/1557988314539000
Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International index of erectile function. Urology. 1999;54(2):346-351. 10.1016/s0090-4295(99)00099-0
Cooke PS, Nanjappa MK, Ko C, Prins GS, Hess RA. Estrogens in male physiology. Physiol Rev. 2017;97(3):995-1043. 10.1152/physrev.00018.2016
Chen HR, Tian RH, Li P, Chen HX, Xia SJ, Li Z. Estradiol is an independent risk factor for organic erectile dysfunction in eugonadal young men. Asian J Androl. 2020;22(6):636-641. 10.4103/aja.aja_135_19
Wu F, Chen T, Mao S, Jiang H, Ding Q, Xu G. Levels of estradiol and testosterone are altered in Chinese men with sexual dysfunction. Andrology. 2016;4(5):932-938. 10.1111/andr.12195
Vignozzi L, Filippi S, Comeglio P, et al. Estrogen mediates metabolic syndrome-induced erectile dysfunction: a study in the rabbit. J Sex Med. 2014;11(12):2890-2902. 10.1111/jsm.12695
Yafi FA, Jenkins L, Albersen M, et al. Erectile dysfunction. Nat Rev Dis Primer. 2016;2:16003. 10.1038/nrdp.2016.3
Finkelstein JS, Lee H, Burnett-Bowie SAM, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011-1022. 10.1056/NEJMoa1206168
Rowland D, McMahon CG, Abdo C, et al. Disorders of orgasm and ejaculation in men. J Sex Med. 2010;7(4 pt 2):1668-1686. 10.1111/j.1743-6109.2010.01782.x
Capogrosso P, Ventimiglia E, Cazzaniga W, Montorsi F, Salonia A. Orgasmic dysfunction after radical prostatectomy. World J Mens Health. 2017;35(1):1-13. 10.5534/wjmh.2017.35.1.1
Veening JG, de Jong TR, Waldinger MD, Korte SM, Olivier B. The role of oxytocin in male and female reproductive behavior. Eur J Pharmacol. 2015;753:209-228. 10.1016/j.ejphar.2014.07.045
IsHak WW, Berman DS, Peters A. Male anorgasmia treated with oxytocin. J Sex Med. 2008;5(4):1022-1024. 10.1111/j.1743-6109.2007.00691.x
Vignozzi L, Filippi S, Luconi M, et al. Oxytocin receptor is expressed in the penis and mediates an estrogen-dependent smooth muscle contractility. Endocrinology. 2004;145(4):1823-1834. 10.1210/en.2003-0962
Filippi S, Morelli A, Vignozzi L, et al. Oxytocin mediates the estrogen-dependent contractile activity of endothelin-1 in human and rabbit epididymis. Endocrinology. 2005;146(8):3506-3517. 10.1210/en.2004-1628
Randolph JF, Zheng H, Avis NE, Greendale GA, Harlow SD. Masturbation frequency and sexual function domains are associated with serum reproductive hormone levels across the menopausal transition. J Clin Endocrinol Metab. 2015;100(1):258-266. 10.1210/jc.2014-1725
Huang A, Yaffe K, Dunn EJ, Are gonadal steroids linked with orgasm perceptions and sexual assertiveness in women and men? Horm Behav. 2009;56(2):206-213. doi:10.1016/j.yhbeh.2009.04.007
Demers LM, Hankinson SE, Haymond S, et al. J Clin Endocrinol Metab. 2015;100(6):2165-2170. 10.1210/jc.2015-1040
Rochira V, Carani C. Aromatase deficiency in men: a clinical perspective. Nat Rev Endocrinol. 2009;5(10):559-568. 10.1038/nrendo.2009.176
Carani C, Rochira V, Faustini-Fustini M, Balestrieri A, Granata AR. Role of oestrogen in male sexual behaviour: insights from the natural model of aromatase deficiency. Clin Endocrinol (Oxf). 1999;51(4):517-524. 10.1046/j.1365-2265.1999.00849.x
Carani C, Granata ARM, Rochira V, et al. Sex steroids and sexual desire in a man with a novel mutation of aromatase gene and hypogonadism. Psychoneuroendocrinology. 2005;30(5):413-417. 10.1016/j.psyneuen.2004.10.004
Rochira V, Granata ARM, Madeo B, Zirilli L, Rossi G, Carani C. Estrogens in males: what have we learned in the last 10 years? Asian J Androl. 2005;7(1):3-20. 10.1111/j.1745-7262.2005.00018.x
Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev. 1999;20(3):358-417. 10.1210/edrv.20.3.0370
Rosner W, Hankinson SE, Sluss PM, Vesper HW, Wierman ME. Challenges to the measurement of estradiol: an endocrine society position statement. J Clin Endocrinol Metab. 2013;98(4):1376-1387. 10.1210/jc.2012-3780